Value of blood‐based biomarker testing to diagnose, identify and monitor patients with Alzheimer's Disease ‐ A structured literature review

Increasingly, evidence demonstrates the diagnostic performance of BBM in AD, showing a correlation with PET and CSF as well as clinical utility and economic value. The available evidence supports clinical adoption of BBM in routine patient care including testing patients to select those for targeted AD therapies. Further, payers should facilitate patient access by evaluating reimbursement of BBM for use in AD diagnosis and management.